Antimicrobial resistance in Europe – Which policies will prove most effective in tackling this issue?
The first case of antibiotic resistance was reported more than 75 years ago but although cases kept cropping up, no mitigatory measures were implemented to combat this rapidly evolving issue.
Chronic misuse and overuse of existing antibiotics, combined with a lack of stringent laws to curb inappropriate utilization/prescription, has now resulted in widespread resistance to most, if not all, antibiotics/antimicrobials.
Antimicrobial Resistance (AMR) is now a major global threat and in recent years countries have finally started to spring into action to fight this issue. But what impact are these initiatives having?
For our latest Free Thinking white paper, we reached out to 10 payers from our global network, plus 178 physicians treating infectious diseases in key European countries (France, Germany, Spain, Italy, and the UK), to identify the initiatives underway to address this challenge in their countries and understand payers’ perceptions of their impact.
Download the white paper.
Other insights.
Jump to a slide with the slide dots.
How we facilitated mock negotiations with payers to improve the pricing strategy for a new biologic in Latin America
Our client had developed the first targeted (biologic) therapy for an immunological condition that could be used.
Read moreCOVID-19 vaccine pricing post pandemic – Payers’ expectations
Back in June 2020, we took an in-depth look at the unprecedented challenge of pricing a coronavirus vaccine.
Read moreSign up to receive Rapport.
Rapport is our monthly newsletter where we share our latest expertise and experience.